Impact of an antibiotic restriction policy on hospital expenditures and bacterial susceptibilities: A lesson from a pediatric institution in a developing country

Pediatric Infectious Disease Journal

Volumn 19, Issue 3, 2000, Pages 200-206

  Sáez Llorens, Xavier ^a   Castrejón De Wong, Maria M ^a   Castaño, Elizabeth ^a   De Suman, Onix ^a   De Morös, Daysi ^a   De Atencio, Iris ^a  

^a UNIVERSIDAD DE PANAMÁ   (Panama)

Author keywords

Antibiotic restriction policy; Bacterial resistance to antibiotics; Hospital expenditures of antibiotics; Panama

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; CEFALOTIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLINDAMYCIN; GENTAMICIN; IMIPENEM; OXACILLIN; PENICILLIN G; PIPERACILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; DRUG COST; DRUG UTILIZATION; HEALTH CARE COST; HEALTH CARE POLICY; HOSPITAL RUNNING COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MORTALITY; NONHUMAN; PANAMA; PEDIATRIC HOSPITAL; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; COST SAVINGS; CROSS INFECTION; DEVELOPING COUNTRIES; DRUG COSTS; DRUG RESISTANCE, MICROBIAL; HOSPITAL COSTS; HOSPITALS, PEDIATRIC; HOSPITALS, TEACHING; HUMANS; LENGTH OF STAY; ORGANIZATIONAL POLICY; PANAMA; RETROSPECTIVE STUDIES;

EID: 0343619409     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200003000-00005     Document Type: Article

References (27)

1. John JF, Fishman NO. Programmatic role of the infectious disease physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997;24:471-85.
2. Baum C, Kennedy DK, Knapp DE, et al. Drug utilization in the United States, 1985, DHHS. Rockville, MD: Food and Drug Administration/National Center for Drugs and Biologics, 1986.
3. Salama S, Roststein C, Mandell L. A multi-disciplinary hospital-based antimicrobial use program: impact on hospital pharmacy expenditures and drug use. Can J Infect Dis 1996;7:104-9.
4. Kislak JW, Eickhoff TC, Finland M. Hospital-acquired infections and antibiotic usage in the Boston City Hospital: January 1964. N Engl J Med 1964;271:834-5.
5. McGowan JE. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol 1994;15:478-83.
6. Kunin CM, Johansen KS, Worning AM, Daschner FD. Report of a symposium on use and abuse of antibiotics worldwide. Rev Infect Dis 1990;12:12-19.
7. Cohen ML. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 1992;257:1050-5.
8. Murray BE. Can antibiotic resistance be controlled? Editorial. N Engl J Med 1994;330:1229-30.
9. Bamberger DM, Dahl SL. Impact of voluntary vs. enforced compliance of third-generation cephalosporin use in a teaching hospital. Arch Intern Med 1992;152:554-7.
10. Clinton White A, Altmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997;25:230-9.
11. Howrie DL, Schwinghammer TL. Cephalosporin use and restriction in pediatric hospitals. Am J Hosp Pharm 1985;42: 1576-8.
12. Sáez-Llorens X, Castaño E, Suman O. Susceptibilidad antimicrobiana de bacterias aisladas en el Hospital del Niño durante 1995. Guias de bolsillo, 1996.
13. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests: approved standards. NCCLS Document M2-A6. Villanova, PA: National Committee for Clinical Laboratory Standards, 1993.
14. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA 1996;275:234-40.
15. Miller JM, Thornsberry C, Baker CN. Disk diffusion susceptibility test troubleshooting guide. Lab Med 1984;15:183-5.
16. Swenson JM, Hindler JA, Peterson LR. Special tests for detecting antibacterial resistance. In: Murray PR, Baron EJ, Pfaller MA, et al., eds. Manual of clinical microbiology. 6th ed. Washington, DC: American Society for Microbiology, 1995:1356-67.
17. CDC. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR 1997;46:626-35.
18. CDC Update. Staphylococcus aureus with reduced susceptibility to vancomycin: United States,1997. MMWR 1997;46: 813.
19. Schwalbe RS, Ritz WJ, Verma PR, Barranco EA, Gilligan PH. Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus. J Infect Dis 1990;161:45-51.
20. Uttley AHC, George RC, Naidoo J, et al. High-level vancomycin-resistant enterococci causing hospital infection. Epidemiol Infect 1989;1103:173-81.
21. Rubin LG, Tucci V, Cercenado E, Eliopoulos G, Isenberg HD. Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect Control Hosp Epidemiol 1992;13:700-5.
22. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350: 1670-3.
23. Powell KR, Pincus PH. Five years of experience with the exclusive use of amikacin in a neonatal intensive care unit. Pediatr Infect Dis J 1987;6:461-6.
24. Peetermans WE, Bobbaers HJ. Amikacin as first-choice aminoglycoside in a medical intensive care unit: a one-year bacteriological surveillance study. J Chemother 1996;8:17-24.
25. Richards MJ, Edwards JR, Culver DH, Gaynes RP, and the National Nosocomial Infections Surveillance System. Pediatrics 1999;103:39-47.
26. Ayliffe GAJ. The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1997; 24(Suppl 1):S74-9.
27. McGowan JE, Carlet J. Antimicrobial resistance: a worldwide problem for health care institutions. Am J Infect Control 1998;26:541-3.